Skip to content
AnalystLens

Illumina Annual Report, Year Ended Dec 31, 2023

Filing Date
Filed February 16, 2024
Period End
December 31, 2023
Security
ILMN
In the record · 2016–202610-K1110-Q338-K167

ILMN filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 167 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Nov ’17Nov ’17
  2. Material agreement8-K · Sep ’20Sep ’20
  3. Leadership change8-K · Sep ’22Sep ’22
  4. Material agreement8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 10-K filed February 16, 2024. Cited figures are marked; the original filing is the authoritative source.

Illumina, Inc. reported fiscal 2023 total revenue of $4,504 milliona, down from $4,584 million in 2022, with a net loss of $1,161 million compared with a net loss of $4,404 million in 2022.

The loss was driven largely by a $827 millionb goodwill and intangible impairment, $712 million of which related to the GRAIL reporting unit, plus $1,069 million of loss from operations. Gross margin fell to 60.9% from 64.8%, reflecting lower fixed-cost leverage on lower manufacturing volumes and lower instrument margins from the NovaSeq X launch. Core Illumina revenue was $4,438 million, down from $4,553 million, while Core Illumina gross margin was 64.4% versus 68.2%.

The filing is dominated by the GRAIL acquisition dispute. The European Commission's October 12, 2023 EC Divestment Decision requires Illumina to divest GRAIL, and on December 17, 2023 the company announced it will do so, with a goal of finalizing terms by the end of the second quarter of 2024. The company has accrued $484 millionc for a €432 million Article 14(2)(b) fine, satisfied through guarantees while under appeal.

Illumina also faces three federal and two state securities class actions, a stockholder derivative suit, an SEC inquiry, and a DOJ civil investigative demand under the False Claims Act. Liquidity remained adequate, with cash and cash equivalents of $1,048 milliond at year-end, down $963 million, after repaying $500 million of 2023 Term Notes and $750 million of convertible notes.

The company says current cash, short-term investments, operating cash flow, and undrawn credit facility capacity should fund needs for at least the next 12 months. No share repurchases were made in 2023, and the company does not intend to make any in 2024.

02—Key points

Key Highlights

  1. Revenue declined 2% to $4,504 million from $4,584 million, with consumables down to $3,083 million and instruments to $704 million in the consolidated statements.
  2. Gross margin contracted to 60.9% from 64.8%, driven by less fixed-cost leverage and lower instrument margins from the NovaSeq X launch.
  3. Net loss narrowed to $1,161 million from $4,404 million, largely because goodwill and intangible impairment fell to $827 million from $3,914 million.
  4. GRAIL divestiture was announced December 17, 2023, with a goal of finalizing terms by the end of Q2 2024; there is no assurance regarding timing.
  5. A €432 million (approximately $484 million accrued) European Commission fine remains under appeal, with guarantees provided in lieu of cash payment.
  6. Year-end cash and cash equivalents were $1,048 million, and the company says it has sufficient liquidity for at least the next 12 months.
  7. New legal exposure includes securities class actions, a stockholder derivative suit, an SEC investigation, and a DOJ civil investigative demand received January 18, 2024.

03—Questions

Frequently Asked Questions

  1. Why did Illumina record such a large loss in 2023?

    The net loss of $1,161 million was driven mainly by $827 million of goodwill and intangible impairment, including a $712 million goodwill impairment for the GRAIL reporting unit recorded in Q3 2023, as well as $1,069 million of loss from operations. The impairment followed a decline in the company's stock price and market capitalization and a higher discount rate applied to GRAIL.

  2. What is the status of the GRAIL divestiture?

    Illumina announced on December 17, 2023 that it will divest GRAIL through a third-party sale or capital markets transaction under the EC Divestment Decision, with the goal of finalizing terms by the end of Q2 2024. Completion requires European Commission approval and other regulatory clearances, and the filing states there can be no assurance regarding timing.

  3. How does the company plan to handle the European Commission fine?

    The fine of approximately €432 million, equal to the maximum 10% of fiscal 2022 consolidated revenues, was imposed under Article 14(2)(b) of the EU Merger Regulation. Illumina provided guarantees in October 2023 in lieu of cash payment while it appeals, accrued $484 million including FX losses and interest, and the fine accrues interest at 5.5% per annum.

  4. How is Illumina's liquidity position?

    Cash and cash equivalents were $1,048 million at December 31, 2023, down from $2,011 million, after repaying $500 million of 2023 Term Notes and $750 million of 2023 Convertible Notes. The company has a $750 million revolving Credit Facility with no borrowings outstanding, and it expects existing resources and operating cash flow to fund needs for at least 12 months.

  5. What new legal and regulatory matters should investors watch?

    The filing discloses three federal securities class actions, two state securities class actions, and a stockholder derivative complaint tied to the GRAIL acquisition. It also notes an SEC investigation that began in July 2023 and a DOJ civil investigative demand received January 18, 2024 under the False Claims Act concerning alleged misrepresentations of cybersecurity compliance to the FDA and other agencies.

04—Continue

← View all 10-K filings